Alemtuzumab for cytolytic induction of immunosuppression in heart transplant recipients

Progress in Transplantation

Volumn 22, Issue 4, 2012, Pages 344-350

  Cahoon, W D ^a   Ensor, C R ^b   Shullo, M A ^c  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; IMMUNOLOGY; REVIEW;

ANTIBODIES, MONOCLONAL, HUMANIZED; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 84870415596     PISSN: 15269248     EISSN: None     Source Type: Journal    
DOI: 10.7182/pit2012241     Document Type: Review

References (25)

1. Denton MD, Magee CC, Sayegh MH. Immunosuppressive strategies in transplantation. Lancet. 1999;353(9158):1083-1091.
2. Gabardi S, Martin ST, Roberts KL, Grafals M. Induction immunosuppressive therapies in renal transplantation. Am J Health Syst Pharm. 2011;68(3):211-218.
3. Patel JK, Kittleson M, Kobashigawa JA. Cardiac allograft rejection. Surgeon. 2011;9(3):160-167.
4. Lindenfeld J, Miller GG, Shakar SF, et al. Drug therapy in the heart transplant recipient: part 1: cardiac rejection and immunosuppressive drugs. Circulation. 2004;110(24):3734-3740.
5. Ippoliti G, Pellegrini C, Nieswandt V. Controversies about induction therapy. Transplant Proc. 2011;43(6):2450-2452.
6. Yamani MH, Taylor DO, Czerr J, et al. Thymoglobulin induction and steroid avoidance in cardiac transplantation: results of a prospective, randomized, controlled study. Clin Transplant. 2008;22(1):76-81.
7. Zuckermann AO, Aliabadi AZ. Calcineurin-inhibitor minimization protocols in heart transplantation. Eur Soc Organ Transpl Int. 2009;22(1):78-89.
8. Singh TP, Faber C, Blume ED, et al. Safety and early outcomes using a corticosteroid-avoidance immunosuppression protocol in pediatric heart transplant recipients. J Heart Lung Transplant. 2010;29(5):517-522.
9. Stehlik J, Edwards LB, Kucheryavaya AY, et al. The registry of the international society for heart and lung transplantation: twenty-eighth adult heart transplant report-2011. J Heart Lung Transplant. 2011;30(10):1078-1094.
10. Kirk AD. Induction immunosuppression. Transplantation. 2006; 82(5):593-602.
11. Ensor CR, Cahoon WD Jr, Hess ML, Kasirajan V, Cooke RH. Induction immunosuppression for orthotopic heart transplantation: a review. Prog Transplant. 2009;19(4):333-342.
12. Magliocca JF, Knechtle SJ. The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation. Transpl Int. 2006;19(9):705-714.
13. Agarwal A, Shen LY, Kirk AD. The role of alemtuzumab in facilitating maintenance immunosuppression minimization following solid organ transplantation. Transplant Immunol. 2008;20(1-2):6-11.
14. LaMattina JC, Mezrich JD, Hoffman RM, et al. Alemtuzumab as compared to alternative contemporary induction regimens. Transpl Int. 2012;25(5):518-526.
15. Calne R, Friend P, Moffatt S, et al. Prope tolerance, peri-operative campath 1H, and low-dose cyclosporine monotherapy in renal allograft recipients. Lancet. 1998;351(9117):1701-1702.
16. Woodside KJ, Lick SD. Alemtuzumab (Campath 1H) as successful salvage therapy for recurrent steroid-resistant heart transplant rejection. J Heart Lung Transplant. 2007;26(7): 750-752.
17. Pham SM, Jimenez J, Bednar BM, et al. Campath-1H in clinical heart transplantation [abstract]. J Heart Lung Transplant. 2006;25(suppl):S126.
18. Pham SM, Bednar BM, Panos A, et al. A randomized study using humanized monoclonal antibody against Cd52 (Campath-1h) and tacrolimus in heart transplant recipients. J Heart Lung Transplant. 2010;29(suppl):S50.
19. Aggarwal S, Luftman K, Bowles R, et al. Mid-term results of Campath induction and steroid-free maintenance immunosuppression in cardiac transplantation. J Heart Lung Transplant. 2010;29(suppl 2):S103.
20. Teuteberg JJ, Shullo MA, Zomak R, et al. Alemtuzumab induction prior to cardiac transplantation with lower intensity maintenance immunosuppression: one-year outcomes. Am J Transplant. 2010;10(2):382-388.
21. Shullo MA, Zomak R, Bhama JK, et al. Alemtuzumab induction facilitates steroid-free immunosuppression in human cardiac transplantation: two year outcomes. J Heart Lung Transplant. 2010;29(suppl 2):S102-S103.
22. Teuteberg JJ, Zomak R, Navoney M, et al. Steroid-free immunosuppression after routine alemtuzumab induction in cardiac transplantation: three year outcomes. J Heart Lung Transplant. 2011;30(suppl 4):S74-S75.
23. Teuteberg JJ, Zomak R, Yost C, et al. Alemtuzumab induction facilitates steroid-free immunosuppression in human cardiac transplantation: four year outcomes. J Heart Lung Transplant. 2012;31(suppl 4):S75-S76.
24. Muzaffar M, Taj A, Ratnam S. Aggressive posttransplant lymphoproliferative disease in a renal transplant patient treated with alemtuzumab. Am J Ther. 2010;17(6):e220-233.
25. Marks WH, Ilsley JN, Dharnidharka VR. Posttransplantation lymphoproliferative disorder in kidney and heart transplant recipients receiving thymoglobulin: a systematic review. Transplant Proc. 2011;43(5):1395-1404.